Comment on: Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial
J Antimicrob Chemother
.
2021 Jan 1;76(1):276-277.
doi: 10.1093/jac/dkaa327.
Authors
Bruno Mégarbane
1
,
Jean-Michel Scherrmann
2
Affiliations
1
Department of Medical and Toxicological Critical Care, Lariboisière Hospital, Federation of Toxicology APHP, University of Paris, INSERM UMRS-1144, Paris, France.
2
Faculty of Pharmacy, University of Paris, INSERM UMRS-1144, Paris, France.
PMID:
32766679
PMCID:
PMC7454555
DOI:
10.1093/jac/dkaa327
No abstract available
Publication types
Comment
MeSH terms
COVID-19*
Coronavirus Infections* / epidemiology
Humans
Hydroxychloroquine
Pandemics
Pneumonia, Viral*
SARS-CoV-2
Substances
Hydroxychloroquine